

Trimel Pharmaceuticals

Pharma & biotech
21 February 2014

Funding ahead of key drivers in H114

Trimel is raising C\$10.5m in equity (C\$0.711/share) following an 80% share price gain since the US regulatory pathway for CompleoTRT was resolved and agreement disputes with M&P were settled. Further potential returns in H114 will be geared towards the results of the Tefina Phase II ambulatory trial (Q214) and the FDA's decision (PDUFA date 28 May) on CompleoTRT.

CompleoTRT dose and PDUFA date clarified

Trimel decided, following discussions with FDA officials, to focus its CompleoTRT (a testosterone replacement therapy) regulatory submission on a three-times daily (TID) dosing schedule. FDA officials had raised questions over the drug's ability to normalise testosterone in a Phase III study (n=306) when used twice-daily (BID), whereas the TID data were more robust. This pushed the PDUFA target action date back to 28 May 2014 (from 28 February), but in our view improves the product's likelihood of gaining approval. While a TID label could affect convenience vs current topical TR products (generally dosed once-daily), once CompleoTRT is approved, a process to extend the label to BID dosing could be initiated.

Out-licensing deal likely to hinge on FDA decision

Added clarity on the CompleoTRT approval strategy should improve Trimel's prospects in partnering discussions, although we believe a transaction is more likely to occur after FDA approval (given de-risking benefits for a potential licensee).

Tefina ambulatory study results in late Q214

Trimel recently completed recruitment for the 240-patient, 84-day Tefina ambulatory [Phase II study](#) in anorgasmia/female orgasmic disorder (FOD). Positive results in Q214 could lead to partnership discussions and future trials. While there is little clarity on acceptable FDA endpoints for FOD, the FDA's recent guidance to Sprout Pharmaceuticals for a re-submission of a previously rejected FSD drug candidate, flibanserlin, signals a potentially more flexible stance by the regulator on FSD drugs.

Valuation: Recovering EV of C\$101m

Trimel's shares have now recovered the losses suffered in October 2013 when the FDA queried the CompleoTRT NDA. We estimate that after the capital raise and a US\$4.25m payment to M&P Patent to settle their legal disputes, current net cash (pro forma) is ~US\$17.5m. This should be sufficient to fund operations into Q414, and provide the flexibility to assess different out-licensing options for CompleoTRT.

Consensus estimates

Year end	Revenue (US\$m)	PBT (US\$m)	EPS (US\$)*	DPS (US\$)	P/E (x)	Yield (%)
12/11	0.0	(26.01)	(0.39)	0.0	N/A	N/A
12/12	0.0	(28.13)	(0.32)	0.0	N/A	N/A
12/13e	0.0	(28.60)	(0.23)	0.0	N/A	N/A
12/14e	5.12	(21.13)	(0.08)	0.0	N/A	N/A

Source: Bloomberg. Note: *Does not reflect February 2014 private placement.

Price C\$0.74
Market cap C\$121m

C\$1.10/US\$

Share price graph



Share details

Code	TRL
Listing	TSX
Shares in issue	163.1m (post 14.8m private placement)

Business description

Trimel Pharmaceuticals is a Canadian specialty pharmaceutical firm. Its lead products, CompleoTRT and Tefina, both deliver testosterone through a bio-adhesive intranasal gel drug delivery platform for male hypogonadism and female sexual dysfunction (FSD)/female orgasmic disorder (FOD), respectively.

Bull

- CompleoTRT different from competitors, may avoid a "black box" label warning.
- Tefina targets an area of high unmet need and has positive data from the VTS study.
- CompleoTRT Phase III study met FDA guidance for testosterone replacement (TR) therapy.

Bear

- Uncertainty for CompleoTRT approval and timing given FDA concerns on BID-to-TID titration group and increasing scrutiny on long-term health risks (eg cardiovascular) associated with TR therapy.
- Financing likely required before year end 2014 unless CompleoTRT partnership deal is finalised.
- Uncertainty on acceptable endpoints by regulators for FSD/FOD.

Analysts

Pooya Hemami	+1 646 653 7026
Christian Glennie	+44 (0)20 3077 5727
Robin Davison	+44 (0)20 3077 5737

healthcare@edisongroup.com

QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Trimer Pharmaceuticals and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is/is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2013]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.